We are the first pure-play animal health venture capital investor.
We support the increasing number of entrepreneurs in the animal health space to develop and grow their business.
Animal health is closely linked to the health and wellbeing of humans. It impacts us in both livestock production and companion animal care.
By 2050, the world will need to double food production to feed a global population estimated to be 9.1 billion*. Meeting this demand involves the cost-effective production of safe, high-quality animal protein.
Our pets are part of our family and provide us with loyalty, companionship, love and affection. They can make our lives feel fuller and happier than ever, teaching us and making us happier and better.
The animal health space has developed over the past few years into a vibrant economic environment affecting billions of people worldwide.
* Source: United Nations World Population Prospects: The 2008 Revision Population Database; USDA World Markets Livestock and Poultry; Census Bureau Int Meat Consumption; FAO The State of Food and Agriculture Report
George Gunn retired from his role on the Executive Committee of Novartis AG during 2015. He has previously held leadership roles in Johnson and Johnson and Pharmacia, and prior to his 32 years in the pharmaceutical industry, worked for nine years as a veterinarian having graduated from the Royal Dick School of Veterinary Studies in 1973. He is a native of the Shetland Islands, Scotland, and has lived and worked in Europe and the USA. During his career he has held various leadership positions within industry associations and, in 2008, was awarded an Honorary Doctorate in Veterinary Medicine and Surgery by the University of Edinburgh. George is founder and CEO of Stonehaven Consulting AG, non-executive Chairman of Virovet BVBA, non-executive Chairman of Nuritas and is a non-executive director of Phibro Animal Health Corporation, Diversigen Inc., and Sidai Africa Ltd.
Jarne Elleholm is a Founding Partner of CAH Capital with more than 25 years of experience in the life sciences industry. His experience includes five years as Managing Partner in a Danish venture capital fund, managing three separate funds with 24 portfolio companies and €110 million AUM. He has also served eight years as Chairman of the Board of animal health diagnostics company, Scandinavian Micro Biodevices. Prior experience includes completing an IPO as CEO of biotech company Areas A/S, developing European sales as Vice President, Europe, for Whatman Ltd. (acquired by GE Healthcare), and driving profitable growth as Vice President and Managing Director of Lundbeck UK Ltd. Jarne has strong venture capital experience developing several companies to successful exits. Jarne holds two bachelor’s degrees from Copenhagen Business School, as well as an MBA from INSEAD.
Matthias Hofer is Founding Partner at CAH Capital. He has 15 years of experience in the animal health industry. He held positions at Novartis Animal Health in Australia, Switzerland and the United Kingdom, including Global Head of Strategy and Global Head of the AquaHealth division at Novartis Animal Health. Later he was Global Leader Emerging Business at Elanco, an area with an annual turnover of $350mn- $400mn. Matthias served on the global executive committees of both Novartis Animal Health and Elanco for seven years. For the past three years, Matthias has been a Partner at Stonehaven Consulting AG. During that time, Stonehaven has grown exponentially and has become one of the leading animal health strategy consulting firms globally. In addition, Matthias is a Co-Founder and Chairman of Stonehaven Incubate AG and board member at Anizome LLC, USA, and bamix® of Switzerland. Matthias has a strong passion for the animal health industry and for making innovation work. He studied business administration at the University of St. Gallen in Switzerland and lives with his wife and two children in Switzerland.
Christof Wolfer is partner at CAH Capital and has more than 25 years of experience in the Swiss banking industry, with a strong focus on finance and governance. Before joining CAH Capital, he worked in various management positions at UBS AG, Switzerland, for 22 years. Until 2002, he developed and managed a 250 million CHF venture capital fund for UBS for four years, and later led the business unit covering large multinational corporates. In this role he managed a team of 50 people, was responsible for a multibillion CHF turnover and governance of a sensitive area (permanent insider). Later as Head of Global Family Office Corporates, he enabled complex transactions including direct investments in private equity for family offices. Prior to joining UBS AG, Christof worked at Price Waterhouse Coopers as an auditor. He holds an MBA from the University of Zurich and is a certified accountant.
Throughout his career, Dr. Reinhard Ambros has gained broad experience in international leadership positions in venture capital, corporate strategy, BD&L and pharmaceutical product development. He serves on the board of public and private bio-technology companies in Europe and the USA. He also serves as advisor to German and Swiss government biotechnology funds. Dr. Ambros retired recently from Novartis where he built, over the past 12 years, the Novartis Venture Fund to the leading corporate biotechnology fund.
Dr. Reinhard Ambros
Dr. Joe McCracken advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives. He also serves on the boards of Alkahest, Inc., EdiGENE Corporation, Kindred Biosciences, Regimmune Inc., and Savara Pharmaceuticals. Dr. McCracken was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. From October 2009 until July 2011, he was General Manager for Roche Pharma Japan & Asia Regional Head, Roche Partnering. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech, for more than 10 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. He holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology, and a Doctorate in Veterinary Medicine from The Ohio State University.
Dr. Joe McCracken
Alan MacKay has been a private equity investor for 30 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, Stockholm, upon the acquisition of Sweden’s largest listed private equity company Atle AB in 2001. Alan has served on the boards of several healthcare companies, including most recently Phibro Animal Health Corporation, which completed a successful initial public offering in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private-equity-backed healthcare. Alan holds a Bachelor’s degree in law, an MSc in enterprise and is a graduate of the Advanced Management Programme at INSEAD. He was Chair of the BVCA for 2016-2017 and has chaired its Responsible Investment Advisory Board.
Jonathan Symonds was appointed as Deputy Group Chairman of HSBC Holdings plc in August 2018 and has been an independent non-executive Director since April 2014. He has extensive international financial and governance experience. Jonathan was previously Chairman of HSBC Bank plc, HSBC’s European subsidiary, which offers services to clients in the UK and Continental Europe. He was Chief Financial Officer of Novartis AG from 2009 to 2013. Before joining Novartis, he was a Partner and Managing Director of Goldman Sachs; Chief Financial Officer of AstraZeneca plc; and a Partner at KPMG. His governance experience includes roles as non-executive Director and chair of the audit committees of Diageo plc and QinetiQ plc. He is currently Chairman of Proteus Digital Health Inc. and a non-executive director of Genomics England Limited. He is also a non-executive director of Rubius Therapeutics, Inc. Jonathan is a Fellow of the Institute of Chartered Accountants in England and Wales. He has a BA, First Class Honours in Business Finance from the University of Hertfordshire.
Jonathan Symonds CBE
Charlbury Animal Health GmbH